BlackRock’s 30 Most Important AI Stocks Right Now

27. Tempus AI Inc. (NASDAQ:TEM)

Weight in ARTY ETF: 0.92%

Number of Hedge Fund Holders: 33

Tempus AI Inc. (NASDAQ:TEM) is one of BlackRock’s 30 most important AI stocks right now. BlackRock holds a 5.14% stake in the company, with 8.97 million shares as of March 31, 2026. However, Cathie Wood’s ARK Investment Management controls a slightly higher stake at 5.51%, making BlackRock the second-largest institutional holder.

Tempus became an investor favorite as an innovative healthcare technology company that uses artificial intelligence to advance precision medicine. The company’s USP rests on its unique data platform that positions it at the intersection of AI, healthcare, and biotechnology, and thus, investors see significant long-term prospects.

Continuing its endeavors toward precision medicine, the company announced on June 25 a research collaboration with Angiosarcoma Awareness, a patient-driven organization that funds research and raises awareness of Angiosarcoma. Under the collaboration, the organization will broaden its understanding of angiosarcoma biology using Tempus AI Inc.’s (NASDAQ:TEM) extensive database, computing, and analytical capabilities, which should help it conduct research at a much faster pace.

According to the company’s release, the collaboration could help researchers find “biological patterns and potential therapeutic opportunities that are difficult to detect in smaller, more fragmented datasets.”

The stock has underperformed year to date, with a -3.30% return, and analyst views are mixed, with close to 60% of analysts recommending a Buy. Earlier, in the first week of June, analysts at Canaccord said the stock doesn’t reflect the true value of the company’s platform, which helps companies accelerate drug development.

Tempus AI Inc. (NASDAQ:TEM) is a healthcare technology company that offers software tools such as the Tempus platform, Next, Algos, Lens, and Hub. The company offers diagnostic services, including solid tumor and hematologic testing through multiple assays. It also offers genetic tests focused on inherited conditions and clinical trial matching services.